ZURA · NASDAQ · Biotechnology

ZuraBio (ZURA)

Develops licensed antibody candidates for autoimmune and inflammatory diseases.

$5.59
Pre-market−0.08 (−1.50%)
At close$5.68(+0.44%)

Something off on this page? Send us feedback.

Next report
Nov 12, 2026
estimated · in 70 days
EPS estimate
−$0.22
Revenue estimate
Fiscal quarter
Q3 FY26

EPSReportedEstimate

Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$0.08−$0.19−$0.17−$0.21−$0.49−$0.22−$0.21Pending
Estimate−$0.16−$0.17−$0.19−$0.19−$0.18−$0.17−$0.19−$0.22
Surprise+50.0%−11.8%+10.5%−10.5%−172.2%−29.4%−9.8%

RevenueReportedEstimate

Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported$2.0KPending
Estimate
Surprise

History

DateEstimateReportedSurprise
Nov 2026−$0.22
Aug 2026−$0.19−$0.21−9.8%
May 2026−$0.17−$0.22−29.4%
Mar 2026−$0.18−$0.49−172.2%
Nov 2025−$0.19−$0.21−10.5%

The latest year is open to everyone — the 17 quarters behind it read with an account.

Sign in
Aug 2025
May 2025
Mar 2025
Nov 2024
Aug 2024
May 2024
Mar 2024
Nov 2023
Aug 2023
May 2023
Mar 2023
Sep 2022
Jun 2022
Mar 2022
Dec 2021
Sep 2021
Jun 2021
Report dateEPS estEPSSurpriseRevenue estRevenueSurpriseReaction
Nov 12, 2026−$0.22
Aug 11, 2026−$0.19−$0.21−9.8%−1.2%
May 7, 2026−$0.17−$0.22−29.4%+5.5%
Mar 19, 2026−$0.18−$0.49−172.2%−10.1%
Nov 13, 2025−$0.19−$0.21−10.5%−2.4%

The latest year is open to everyone — the 17 quarters behind it read with an account.

Sign in
Aug 14, 2025
May 8, 2025
Mar 25, 2025
Nov 7, 2024
Aug 13, 2024
May 9, 2024
Mar 26, 2024
Nov 13, 2023
Aug 14, 2023
May 12, 2023
Mar 31, 2023
Sep 30, 2022
Jun 30, 2022
Mar 30, 2022
Dec 30, 2021
Sep 29, 2021
Jun 29, 2021